Back to results
US 12,668,781 B2Granted
Materials and methods for the manufacture of pluripotent stem cells
AssigneeJanssen Biotech, Inc.
InventorsIqbal S. Grewal, Rajkumar Ganesan, Sanjaya Singh
Life of this patent
Estimating the term…
Abstract
Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (IPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.
Claims9
A method of treating a subject in need thereof comprising:
- (i) obtaining a population of cells comprising peripheral blood mononuclear cells (PBMCs) from the subject;
- (ii) reprogramming γδ T cells in the population of cells to produce iPSCs;
- and
- (iii) administering the produced iPSCs, or a pharmaceutical composition comprising the produced iPSCs to the subject, optionally after differentiating the iPSCs into one or more desired types of cells;
- wherein the step of reprogramming γδ T cells comprises:
- a) purifying Vγ9Vδ2-enriched γδ T cells from the population of cells;
- b) transducing the purified Vγ9Vδ2-enriched γδ T cells with a viral vector encoding one or more reprogramming factors;
- and
- c) culturing the transduced cells under conditions suitable for reprogramming mammalian somatic cells to a pluripotent state, thereby producing iPSCs;
- wherein the produced iPSCs have rearranged TRG and TRD genes;
- wherein the produced iPSCs have TCR rearrangements containing Vγ9 and Vδ2gene segments;
- wherein optionally the subject is a human;
- wherein optionally the subject has a hyperproliferative disorder or a cancer of hematopoietic system;
- and
- wherein optionally the viral vector is a Sendai virus (SeV) vector.
12 more elements
Dependencies are inferred from the claim text.